Page last updated: 2024-08-24

simendan and Cardiotoxicity

simendan has been researched along with Cardiotoxicity in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Deng, W; Hu, C; Li, LL; Tang, QZ; Wei, L; Wei, WY; Zhang, N	1
Chen, Z; Sun, Y; Yang, F; Zhao, LN	1
Andreadou, I; Chavdoula, E; Cokkinos, DV; Davos, CH; Efentakis, P; Farmakis, D; Gioti, K; Iliodromitis, EK; Klinakis, A; Kostomitsopoulos, N; Papapetropoulos, A; Sanoudou, D; Sigala, F; Suter, T; Tasouli, A; Tenta, R; Varela, A; Wenzel, P	1

Reviews

1 review(s) available for simendan and Cardiotoxicity

Article	Year
Levosimendan as a new force in the treatment of sepsis-induced cardiomyopathy: mechanism and clinical application. The Journal of international medical research, 2019, Volume: 47, Issue:5 Topics: Cardiomyopathies; Cardiotonic Agents; Cardiotoxicity; Humans; Prognosis; Sepsis; Simendan	2019

Other Studies

2 other study(ies) available for simendan and Cardiotoxicity

Article	Year
Levosimendan Protects against Doxorubicin-Induced Cardiotoxicity by Regulating the PTEN/Akt Pathway. BioMed research international, 2020, Volume: 2020 Topics: Animals; Cardiotonic Agents; Cardiotoxicity; Cell Line; Doxorubicin; Male; Mice; Mice, Inbred C57BL; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Rats; Signal Transduction; Simendan	2020
Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy. Cardiovascular research, 2020, 03-01, Volume: 116, Issue:3 Topics: Animals; Antibiotics, Antineoplastic; Calcium Signaling; Calcium-Binding Proteins; Cardiotoxicity; Cardiovascular Agents; Cells, Cultured; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart Diseases; Male; Mammary Neoplasms, Experimental; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Myocardial Contraction; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Proto-Oncogene Proteins c-akt; Rats, Wistar; Simendan; Time Factors	2020

Article

Year

Levosimendan Protects against Doxorubicin-Induced Cardiotoxicity by Regulating the PTEN/Akt Pathway.

BioMed research international, 2020, Volume: 2020

Topics: Animals; Cardiotonic Agents; Cardiotoxicity; Cell Line; Doxorubicin; Male; Mice; Mice, Inbred C57BL; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Rats; Signal Transduction; Simendan

2020

Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy.

Cardiovascular research, 2020, 03-01, Volume: 116, Issue:3

Topics: Animals; Antibiotics, Antineoplastic; Calcium Signaling; Calcium-Binding Proteins; Cardiotoxicity; Cardiovascular Agents; Cells, Cultured; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart Diseases; Male; Mammary Neoplasms, Experimental; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Myocardial Contraction; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Proto-Oncogene Proteins c-akt; Rats, Wistar; Simendan; Time Factors

2020